The National Heart Lung and Blood Institute has terminated the intense glycemic control arm of the ACCORD clinical trial due to a 20% increase in the mortality rate.
Swansea University researchers say breath tests could revolutionize early disease diagnosis before any symptoms have developed, and without invasive procedures.